SCHEMBL43400

SCHEMBL43400

O=C(O)CN1CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6361223 1.00 TSHR (0.50)
SCHEMBL948990 0.86 TSHR (0.68)
SCHEMBL948880 0.85 TSHR (0.60)
SCHEMBL13621201 0.84 GAA (0.50)
SCHEMBL11036951 0.83 TSHR (0.58)
SCHEMBL596327 0.83 TSHR (0.58)
SCHEMBL6361822 0.81 PLA2G10 (0.41)
SCHEMBL25497614 0.80 TSHR (0.42)
SCHEMBL26205074 0.80 LMNA (0.40)
SCHEMBL7771566 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0939632-B1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS LILLY CO ELI (US) 2005-10-05 EP claimed
EP-0939632-A4 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS LILLY CO ELI (US) 2002-09-25 EP claimed
US-20020049187-A1 Non-peptidyl vasopressin V1a antagonists BRUNS ROBERT F (US) 2002-04-25 US claimed
US-6204260-B1 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES ELI LILLY AND COMPANY 2001-03-20 US claimed
EP-0939632-A1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS ELI LILLY AND COMPANY (US) 1999-09-08 EP claimed
WO-1997030707-A1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-08-28 WO claimed
JP-59102397-A None JP disclosed
JP-61027960-A None JP disclosed
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2024-04-11 US disclosed
US-20230123729-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2023-04-20 US disclosed
US-11628160-B2 Compositions and methods for treating brain injury AZEVAN PHARMACEUTICALS, INC. (US) 2023-04-18 US disclosed
EP-3122743-B1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2022-11-09 EP disclosed
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases AZEVAN PHARMACEUTICALS, INC. (US) 2022-05-03 US disclosed
EP-0171159-A1 Substituted azetidinone compounds, their preparation, and medicaments containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1986-02-12 EP disclosed
JP-S6127960-A ALPHA-(2-OXO-1-AZETIDINYL)ACETIC ACID DERIVATIVE AND ITS PREPARATION YAMANOUCHI PHARMACEUT CO LTD 1986-02-07 JP disclosed
EP-0150781-A1 6-Alkylidene pemens, their preparation and use, and intermediates BEECHAM GROUP PLC (GB) 1985-08-07 EP disclosed
EP-0116432-A2 Improvements in or relating to N-(substituted-methyl)-azetidin-2-ones THE UNIVERSITY OF NOTRE DAME DU LAC (US) 1984-08-22 EP disclosed
JP-S59102397-A METHOD FOR HYDROLYZING ESTER TEIKOKU HORMONE MFG CO LTD 1984-06-13 JP disclosed
US-4283333-A α-[4-Oxoazetidin-1-yl]-acetic acid compounds useful as intermediates in preparing 1-oxadethiacephalosporins SHIONOGI & CO., LTD. (JP) 1981-08-11 US disclosed
JP-S06127960-A 0001-01-01 JP disclosed